NCT07213375 High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy
| NCT ID | NCT07213375 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Copenhagen University Hospital, Rigshospitalet |
| Condition | Analgetic |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 80 participants in total. It began in 2025-09-01 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim is to conduct a randomized controlled trial (RCT) with a high dose arm (1mg/kg) vs a low dose (8mg in total) of steroid (Dexamethasone) given intravenous (IV) after the induction of anesthesia to "High-pain-responders" in patients undergoing VATS lobectomy/segmentectomy. The hypothesis is that a high dose of Dexamethasone can lower pain when coughing in the morning after VATS lobectomy/segmentectomy, in patients scoring as "High-pain-responders" on the Pain-Catastrophizing-Scale
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 year * Able to understand written and spoken Danish language * PCS ≥20 * Signed written informed consent form. * Patient planned to elective VATS lobectomy/segmentectomy Exclusion Criteria: * Patients undergoing systemic glucocorticoid or other immunosuppressive therapies, ex-cluding inhaled steroids. * Individuals with diabetes requiring insulin treatment. * Pregnant or breastfeeding patients. * Patients with known allergies to the study drug. * Individuals with mental disabilities that may impair their capacity to provide informed consent or compromise the validity of data collection. * Patients with diagnosed schizophrenia, active psychosis, bipolar disorder, or a history of ongoing treatment with antipsychotic and/or antidepressant medications. * Individuals with altered pain perception due to other conditions or injuries, such as spi-nal cord or brain injuries, severe polyneuropathies, or neurological disorders. * Regular users of opioid medications. * Patients requiring reoperation within the first two postoperative days. * Individuals undergoing conversion to a surgical procedure other than VATS lobecto-my/segmentectomy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07213375 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Analgetic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07213375 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07213375 currently recruiting?
Yes, NCT07213375 is actively recruiting participants. Contact the research team at lasse.visby@regionh.dk for enrollment information.
Where is the NCT07213375 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT07213375 clinical trial?
NCT07213375 is sponsored by Copenhagen University Hospital, Rigshospitalet. The trial plans to enroll 80 participants.